Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models
Open Access
- 23 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 22 (1), 1-10
- https://doi.org/10.1186/s13075-020-02178-z
Abstract
In younger individuals, low absolute risk of cardiovascular disease (CVD) may conceal an increased risk age and relative risk of CVD. Calculation of risk age is proposed as an adjuvant to absolute CVD risk estimation in European guidelines. We aimed to compare the discriminative ability of available risk age models in prediction of CVD in rheumatoid arthritis (RA). Secondly, we also evaluated the performance of risk age models in subgroups based on RA disease characteristics. RA patients aged 30–70 years were included from an international consortium named A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Prior CVD and diabetes mellitus were exclusion criteria. The discriminatory ability of specific risk age models was evaluated using c-statistics and their standard errors after calculating time until fatal or non-fatal CVD or last follow-up. A total of 1974 patients were included in the main analyses, and 144 events were observed during follow-up, the median follow-up being 5.0 years. The risk age models gave highly correlated results, demonstrating R2 values ranging from 0.87 to 0.97. However, risk age estimations differed > 5 years in 15–32% of patients. C-statistics ranged 0.68–0.72 with standard errors of approximately 0.03. Despite certain RA characteristics being associated with low c-indices, standard errors were high. Restricting analysis to European RA patients yielded similar results. The cardiovascular risk age and vascular age models have comparable performance in predicting CVD in RA patients. The influence of RA disease characteristics on the predictive ability of these prediction models remains inconclusive.Funding Information
- Eli Lilly (2013064)
- Norwegian South East Health Authority (2013010)
This publication has 38 references indexed in Scilit:
- Usefulness of Risk Scores to Estimate the Risk of Cardiovascular Disease in Patients With Rheumatoid ArthritisThe American Journal of Cardiology, 2012
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studiesAnnals Of The Rheumatic Diseases, 2012
- Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular diseaseAnnals Of The Rheumatic Diseases, 2011
- Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature reviewRheumatology, 2010
- Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritisArthritis Care & Research, 2010
- How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluationEuropean Heart Journal, 2010
- Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severityAnnals Of The Rheumatic Diseases, 2010
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEuropean Heart Journal, 2003
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995